Otofarma SpA (OTO)

Milan

Currency in EUR

2.34

-0.10(-4.10%)

Closed·16:35:25

Fair Value

Unlock Value

Day's Range

2.28

2.48

52 wk Range

2.28

5.72

Otofarma (OTO) Income Statement & Profits

Assess the Otofarma income statement (earnings report) to see how the company performs across operating and non-operating activities, including revenue, expenses and net income. Review OTO diluted EPS and profitability over the last four annual or quarterly periods.

Investors who need greater depth or who want to customise how data is presented to fit their own investment styles are able to do so via their very own InvestingPro account.

Period Ending:

2023

31/12

2024

31/12

Total Revenues

10.13

14.38

Total Revenues Growth

+42%

Cost Of Revenues

7.93

9.7

Gross Profit

2.2

4.69

Gross Profit Growth

+113.49%

Gross Profit Margin %

21.68%

32.6%

Other Operating Expenses, Total

0.95

1.5

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

-	+58.61%
-	-
0.86	1.14
0.03	0.24

Operating Income

1.25

3.19

Operating Income Growth

+155.03%

EBIT Margin %

12.34%

22.16%

Net Interest Expenses

-0.1

-0.11

Net Interest Expenses Growth

-10.91%

Interest Expense, Total

-0.1

-0.11

Interest And Investment Income

Other Non Operating Expenses, Total

EBT, Excl. Unusual Items

1.15

3.08

Gain (Loss) On Sale Of Assets

Other Unusual Items, Total

EBT, Incl. Unusual Items

1.15

3.08

EBT, Incl. Unusual Items Growth

+167.79%

EBT, Incl. Unusual Items Margin

11.35%

21.4%

Income Tax Expense

0.39

0.98

Net Income to Company

0.75

2.1

Minority Interest

Net Income

0.75

2.1

Net Income Growth

+178.25%

Net Income Margin %

7.45%

14.6%

Preferred Dividend and Other Adjustments

Net Income to Common Excl. Extra Items

0.75

2.1

Basic EPS - Continuing Operations

Basic EPS - Continuing Operations Growth

Diluted EPS - Continuing Operations

Diluted EPS - Continuing Operations Growth

Basic Weighted Average Shares Outstanding

Diluted Weighted Average Shares Outstanding

Dividend Per Share

Dividend Per Share Growth

EBITDA

1.3

3.25

EBITDA Growth

+148.86%

EBITDA Margin %

12.88%

22.57%

EBIT

1.25

3.19

* In Millions of EUR (except for per share items)

FTSE 100

10,636.71

-48.17

-0.45%

DAX

25,375.29

+0.87

0.00%

Euro Stoxx 50

6,325.25

+23.97

+0.38%

S&P 500

7,657.49

-26.44

-0.34%

Nikkei 225

65,481.27

-396.35

-0.60%

Dow Jones

51,186.84

-294.67

-0.57%

FTSE 100 Futures

10,665.30

-90.2

-0.84%

Market Movers

Name	Last	Chg. %	Vol.
Shell	3,594.0	-1.66%	16.26M
AstraZeneca	12,428.0	-0.51%	2.70M
Rolls-Royce Holdings	1,481.20	+0.46%	16.49M
Prudential	944.65	+0.49%	20.88M
HSBC	1,513.40	-0.20%	12.80M
BP	550.70	-2.27%	34.51M
British American Tobacco	4,144.0	-1.87%	4.24M

Name	Last	Chg. %	Vol.
National Bank of Greece	17.805	+541.16%	280.00
Investor B	407.40	+115.24%	3.17M
Hellenic Telecommunications	19.78	+72.00%	55.00
BW LPG	235.40	+49.65%	6.56K
Rapid Nutrition	3.2500	+35.42%	6.11K
ALK-Abello B	197.05	+31.85%	24.70K
Mothercare	0.41	+31.61%	36.34M

Name	Last	Chg. %	Vol.
daVictus	1.50	-50.00%	0.00
Sutton Harbour	3.00	-33.33%	136.95K
Litigation Capital	1.66	-21.43%	154.84K
Halo Minerals	7.13	-20.89%	1.11M
Genincode	0.70	-20.00%	22.95M
Beowulf	5.25	-16.00%	32.04K
Tekcapital	2.45	-15.52%	4.65M

Trending Stocks

Name	Last	Chg. %	Vol.
Rolls-Royce Holdings	1,481.20	+0.46%	16.49M
BP	550.70	-2.27%	34.51M
AstraZeneca	12,428.0	-0.51%	2.70M
Medpal AI	7.55	+4.14%	30.45M
Glencore	551.80	+0.05%	20.04M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaa	298.50	+47.13%	439.18
Aaaa Aaaaa	448.10	+41.19%	632.69
Aaaaaaaaaaa Aa Aaaaa	424.50	+40.77%	597.59
Aaa Aa Aaaaaa	2,472.0	+40.40%	3,470.7
Aaaaaaa	438.00	+37.91%	604.04
Aaaaaaaa Aaaa	2,447.00	+37.39%	3,361.91
Aaa A	550.70	+35.58%	746.61

Name	Last	Upside	Fair Value
Aaaaaa	298.50	+47.13%	439.18
Aaaa Aaaaa	448.10	+41.19%	632.69
Aaaaaaaaaaa Aa Aaaaa	424.50	+40.77%	597.59
Aaa Aa Aaaaaa	2,472.0	+40.40%	3,470.7
Aaaaaaa	438.00	+37.91%	604.04
Aaaaaaaa Aaaa	2,447.00	+37.39%	3,361.91
Aaa A	550.70	+35.58%	746.61

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Otofarma SpA (OTO)

Otofarma (OTO) Income Statement & Profits

Trending Stocks